Evidence map›Paper›PMID 34439680›Full record

ArticleBrain sciences2021

An ID-Associated Application to Facilitate Patient-Tailored Management of Multiple Sclerosis.

Michael Lang, Daniela Rau, Lukas Cepek, Fia Cürten, Stefan Ringbauer, Martin Mayr

Abstract read
In one paragraph

Article in Brain sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michael LangNeuroPoint Patientenakademie, 89073 Ulm, Germany.
Daniela RauNeuroPoint Patientenakademie, 89073 Ulm, Germany.
Lukas CepekNeuroPoint Patientenakademie, 89073 Ulm, Germany.
Fia CürtenNeuroSys GmbH, 89081 Ulm, Germany.
Stefan RingbauerNeuroSys GmbH, 89081 Ulm, Germany.
Martin MayrNeuroSys GmbH, 89081 Ulm, Germany.

Funding

PatientConcept system has received financial support from the Bavarian state, Neuropoint Patient Academy and Systemhaus Ulm, Almirall, Alnylam, Bayer, Biogen, Novartis, Roche, Sanofi Genzyme and Teva. NA
6 · The paper itself

Abstract

Despite improvements in diagnosis and treatment, multiple sclerosis (MS) is the leading neurological cause of disability in young adults. As a chronic disease, MS requires complex and challenging management. In this context, eHealth has gained an increasing relevance. Here, we aim to summarize beneficial features of a mobile app recently implemented in clinical MS routine as well as beyond MS. PatientConcept is a CE-certified, ID-associated multilingual software application allowing patients to record relevant health data without disclosing any identifying data. Patients can voluntarily share their health data with selected physicians. Since its implementation in 2018, about 3000 MS patients have used PatientConcept. Initially developed as a physician-patient communication platform, the app maps risk management plans of all current disease modifying therapies and thereby facilitates adherence to specified monitoring appointments. It also allows continuous monitoring of various PROs (Patient Reported Outcomes), enabling a broad overview of the disease course. In addition, various studies/projects currently assess monitoring, follow-up, diagnostics and telemetric evaluations of patients with other diseases beyond MS. Altogether, PatientConcept offers a broad range of possibilities to support physician-patient communication, implementation of risk management plans and assessment of PROs. It is a promising tool to facilitate patient-tailored management of MS and other chronic diseases.

Indexed as

appchronic diseasecommunicationdigital toolsdisease managemente-healthmultiple sclerosisPatient Reported Outcomes

Identifiers

PMID34439680
PMCPMC8392440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.